Medicine
Tiagabine 2 mg tablet
Tiagabine 2 mg tablet is a generic prescription medicine for oral use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F). Protect from light and moisture.
Key facts
- Active ingredient (INN)
- Tiagabine
- Brand
- Sold under the generic name
- Strength
- 2 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 1000 tablets
- Manufacturers
- Sun Pharmaceutical IndustriesIndiaNovadoz PharmaceuticalsIndia
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F). Protect from light and moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N03AG06 Tiagabine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 November 2011
- Identifiers
- RxCUI 1299903, 1299909, 1299911 +1DailyMed set ID 7c034fe0-cdac-49e1-8e39-592846ea3bec, 7eeb2d81-c5d7-46a0-aa5c-149b55df71bdNDC 72205-084, 62756-200Application ANDA214816, ANDA077555
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet in 1 bottle | 72205-084-30 | Novadoz PharmaceuticalsIndia | 23 November 2021 |
| 1000 tablet, film coated in 1 bottle | 62756-200-18 | Sun Pharmaceutical IndustriesIndia | 4 November 2011 |
| 30 tablet, film coated in 1 bottle | 62756-200-83 | Sun Pharmaceutical IndustriesIndia | 4 November 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 September 1997 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Tiagabine
Clinical summary
Tiagabine is an anti-epileptic agent indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. It is available as tablets for oral use. MedsAcross supplies Tiagabine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TiagabineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Tiagabine Hydrochloride prescribing information (Novadoz Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Tiagabine 2 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.